CVM:NYE-CEL-SCI Corp (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.08

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

0.29M

Analyst Target

USD 23.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 609.93B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.82B
RCUS Arcus Biosciences Inc

N/A

USD 1.64B
NUVB Nuvation Bio Inc

N/A

USD 1.03B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.35B
ADCT ADC Therapeutics SA

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.15B
ANVS Annovis Bio Inc

N/A

USD 0.11B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B

ETFs Containing CVM

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.29% 32% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.29% 32% F 2% F
Trailing 12 Months  
Capital Gain -15.63% 52% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.63% 52% F 10% F
Trailing 5 Years  
Capital Gain -87.37% 29% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.37% 29% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -24.08% 21% F 2% F
Dividend Return -24.08% 21% F 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.22% 64% D 19% F
Risk Adjusted Return -51.00% 12% F 6% D-
Market Capitalization 0.08B 63% D 24% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.